[{"path":[]},{"path":"https://sigven.github.io/pharmaOncoX/CODE_OF_CONDUCT.html","id":"our-pledge","dir":"","previous_headings":"","what":"Our Pledge","title":"Contributor Covenant Code of Conduct","text":"members, contributors, leaders pledge make participation community harassment-free experience everyone, regardless age, body size, visible invisible disability, ethnicity, sex characteristics, gender identity expression, level experience, education, socio-economic status, nationality, personal appearance, race, religion, sexual identity orientation. pledge act interact ways contribute open, welcoming, diverse, inclusive, healthy community.","code":""},{"path":"https://sigven.github.io/pharmaOncoX/CODE_OF_CONDUCT.html","id":"our-standards","dir":"","previous_headings":"","what":"Our Standards","title":"Contributor Covenant Code of Conduct","text":"Examples behavior contributes positive environment community include: Demonstrating empathy kindness toward people respectful differing opinions, viewpoints, experiences Giving gracefully accepting constructive feedback Accepting responsibility apologizing affected mistakes, learning experience Focusing best just us individuals, overall community Examples unacceptable behavior include: use sexualized language imagery, sexual attention advances kind Trolling, insulting derogatory comments, personal political attacks Public private harassment Publishing others’ private information, physical email address, without explicit permission conduct reasonably considered inappropriate professional setting","code":""},{"path":"https://sigven.github.io/pharmaOncoX/CODE_OF_CONDUCT.html","id":"enforcement-responsibilities","dir":"","previous_headings":"","what":"Enforcement Responsibilities","title":"Contributor Covenant Code of Conduct","text":"Community leaders responsible clarifying enforcing standards acceptable behavior take appropriate fair corrective action response behavior deem inappropriate, threatening, offensive, harmful. Community leaders right responsibility remove, edit, reject comments, commits, code, wiki edits, issues, contributions aligned Code Conduct, communicate reasons moderation decisions appropriate.","code":""},{"path":"https://sigven.github.io/pharmaOncoX/CODE_OF_CONDUCT.html","id":"scope","dir":"","previous_headings":"","what":"Scope","title":"Contributor Covenant Code of Conduct","text":"Code Conduct applies within community spaces, also applies individual officially representing community public spaces. Examples representing community include using official e-mail address, posting via official social media account, acting appointed representative online offline event.","code":""},{"path":"https://sigven.github.io/pharmaOncoX/CODE_OF_CONDUCT.html","id":"enforcement","dir":"","previous_headings":"","what":"Enforcement","title":"Contributor Covenant Code of Conduct","text":"Instances abusive, harassing, otherwise unacceptable behavior may reported community leaders responsible enforcement [INSERT CONTACT METHOD]. complaints reviewed investigated promptly fairly. community leaders obligated respect privacy security reporter incident.","code":""},{"path":"https://sigven.github.io/pharmaOncoX/CODE_OF_CONDUCT.html","id":"enforcement-guidelines","dir":"","previous_headings":"","what":"Enforcement Guidelines","title":"Contributor Covenant Code of Conduct","text":"Community leaders follow Community Impact Guidelines determining consequences action deem violation Code Conduct:","code":""},{"path":"https://sigven.github.io/pharmaOncoX/CODE_OF_CONDUCT.html","id":"1-correction","dir":"","previous_headings":"Enforcement Guidelines","what":"1. Correction","title":"Contributor Covenant Code of Conduct","text":"Community Impact: Use inappropriate language behavior deemed unprofessional unwelcome community. Consequence: private, written warning community leaders, providing clarity around nature violation explanation behavior inappropriate. public apology may requested.","code":""},{"path":"https://sigven.github.io/pharmaOncoX/CODE_OF_CONDUCT.html","id":"2-warning","dir":"","previous_headings":"Enforcement Guidelines","what":"2. Warning","title":"Contributor Covenant Code of Conduct","text":"Community Impact: violation single incident series actions. Consequence: warning consequences continued behavior. interaction people involved, including unsolicited interaction enforcing Code Conduct, specified period time. includes avoiding interactions community spaces well external channels like social media. Violating terms may lead temporary permanent ban.","code":""},{"path":"https://sigven.github.io/pharmaOncoX/CODE_OF_CONDUCT.html","id":"3-temporary-ban","dir":"","previous_headings":"Enforcement Guidelines","what":"3. Temporary Ban","title":"Contributor Covenant Code of Conduct","text":"Community Impact: serious violation community standards, including sustained inappropriate behavior. Consequence: temporary ban sort interaction public communication community specified period time. public private interaction people involved, including unsolicited interaction enforcing Code Conduct, allowed period. Violating terms may lead permanent ban.","code":""},{"path":"https://sigven.github.io/pharmaOncoX/CODE_OF_CONDUCT.html","id":"4-permanent-ban","dir":"","previous_headings":"Enforcement Guidelines","what":"4. Permanent Ban","title":"Contributor Covenant Code of Conduct","text":"Community Impact: Demonstrating pattern violation community standards, including sustained inappropriate behavior, harassment individual, aggression toward disparagement classes individuals. Consequence: permanent ban sort public interaction within community.","code":""},{"path":"https://sigven.github.io/pharmaOncoX/CODE_OF_CONDUCT.html","id":"attribution","dir":"","previous_headings":"","what":"Attribution","title":"Contributor Covenant Code of Conduct","text":"Code Conduct adapted Contributor Covenant, version 2.0, available https://www.contributor-covenant.org/version/2/0/ code_of_conduct.html. Community Impact Guidelines inspired Mozilla’s code conduct enforcement ladder. answers common questions code conduct, see FAQ https://www.contributor-covenant.org/faq. Translations available https:// www.contributor-covenant.org/translations.","code":""},{"path":"https://sigven.github.io/pharmaOncoX/authors.html","id":null,"dir":"","previous_headings":"","what":"Authors","title":"Authors and Citation","text":"Sigve Nakken. Author, maintainer.","code":""},{"path":"https://sigven.github.io/pharmaOncoX/authors.html","id":"citation","dir":"","previous_headings":"","what":"Citation","title":"Authors and Citation","text":"Nakken S.  (2022)  pharmaOncoX: Targeted non-targeted anti-cancer drugs drug regimens.  R package version 0.9.7.  (https://github.com/sigven/pharmaOncoX)","code":"@Manual{,   title = {pharmaOncoX: Targeted and non-targeted anti-cancer drugs and drug regimens},   author = {Sigve Nakken},   year = {2022},   note = {R package version 0.9.7},   url = {https://github.com/sigven/pharmaOncoX}, }"},{"path":"https://sigven.github.io/pharmaOncoX/index.html","id":"pharmaoncox-","dir":"","previous_headings":"","what":"Annotated targeted and non-targeted anticancer drugs","title":"Annotated targeted and non-targeted anticancer drugs","text":"pharmaOncoX provides access targeted non-targeted cancer drugs, including comprehensive annotations per target, drug mechanism--action, approval dates, clinical trial phases various indications etc. data largely based drug-target-indication associations provided Open Targets Platform (Ochoa et al., Nucleic Acids Res., 2021). Associations retrieved Open Targets Platform limited cancer-relevant indications (provided sigven/oncoPhenoMap). Drug-target associations Open Targets Platform furthermore integrated drug information NCI Thesaurus, append non-targeted cancer drugs (chemotherapies etc.), various drug regimens. Furthermore, provide anti-cancer drugs pharmaOncoX following tentative drug categories/types (necessarily mutually exclusive), indicative mechanism--action: Alkylating agents Angiogenesis inhibitors Anthracyclines Antimetabolites AR antagonists BET inhibitors Hedgehog antagonists HDAC inhibitors Hormone therapies Immune checkpoint inhibitors Kinase inhibitors Monoclonal antibodies PARP inhibitors Platinum compounds Proteasome inhibitors Topoisomerase inhibitors Tubulin inhibitors Currently (September 21st 2022), pharmaOncoX built upon following releases external databases: Open Targets Platform (2022.06) ChEMBL (v31) NCI Thesaurus (22.08e)","code":""},{"path":"https://sigven.github.io/pharmaOncoX/index.html","id":"getting-started","dir":"","previous_headings":"","what":"Getting started","title":"Annotated targeted and non-targeted anticancer drugs","text":"Installation instructions Usage examples","code":""},{"path":"https://sigven.github.io/pharmaOncoX/index.html","id":"contact","dir":"","previous_headings":"","what":"Contact","title":"Annotated targeted and non-targeted anticancer drugs","text":"sigven ifi.uio.","code":""},{"path":"https://sigven.github.io/pharmaOncoX/index.html","id":"code-of-conduct","dir":"","previous_headings":"","what":"Code of Conduct","title":"Annotated targeted and non-targeted anticancer drugs","text":"Please note project released Contributor Code Conduct. participating project agree abide terms.","code":""},{"path":"https://sigven.github.io/pharmaOncoX/reference/get_biomarkers.html","id":null,"dir":"Reference","previous_headings":"","what":"Function that retrieves pharmaOncoX data from Google Drive — get_biomarkers","title":"Function that retrieves pharmaOncoX data from Google Drive — get_biomarkers","text":"Function retrieves pharmaOncoX data Google Drive","code":""},{"path":"https://sigven.github.io/pharmaOncoX/reference/get_biomarkers.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Function that retrieves pharmaOncoX data from Google Drive — get_biomarkers","text":"","code":"get_biomarkers(cache_dir = NA, force_download = F)"},{"path":"https://sigven.github.io/pharmaOncoX/reference/get_biomarkers.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Function that retrieves pharmaOncoX data from Google Drive — get_biomarkers","text":"cache_dir Local directory data download force_download Logical indicating local cache force downloaded (.e. set TRUE re-download even data exists cache)","code":""},{"path":"https://sigven.github.io/pharmaOncoX/reference/get_drug_records.html","id":null,"dir":"Reference","previous_headings":"","what":"Function that retrieves pharmaOncoX data from Google Drive — get_drug_records","title":"Function that retrieves pharmaOncoX data from Google Drive — get_drug_records","text":"Function retrieves pharmaOncoX data Google Drive","code":""},{"path":"https://sigven.github.io/pharmaOncoX/reference/get_drug_records.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Function that retrieves pharmaOncoX data from Google Drive — get_drug_records","text":"","code":"get_drug_records(cache_dir = NA, force_download = F)"},{"path":"https://sigven.github.io/pharmaOncoX/reference/get_drug_records.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Function that retrieves pharmaOncoX data from Google Drive — get_drug_records","text":"cache_dir Local directory data download force_download Logical indicating local cache force downloaded (.e. set TRUE re-download even data exists cache)","code":""},{"path":"https://sigven.github.io/pharmaOncoX/reference/get_on_off_label_drugs.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function to get on-label/off-label drugs (not complete) — get_on_off_label_drugs","title":"Utility function to get on-label/off-label drugs (not complete) — get_on_off_label_drugs","text":"Utility function get -label/-label drugs (complete)","code":""},{"path":"https://sigven.github.io/pharmaOncoX/reference/get_on_off_label_drugs.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function to get on-label/off-label drugs (not complete) — get_on_off_label_drugs","text":"","code":"get_on_off_label_drugs(cache_dir = NA)"},{"path":"https://sigven.github.io/pharmaOncoX/reference/get_on_off_label_drugs.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function to get on-label/off-label drugs (not complete) — get_on_off_label_drugs","text":"cache_dir Local cache directory","code":""},{"path":"https://sigven.github.io/pharmaOncoX/reference/get_onco_drugs.html","id":null,"dir":"Reference","previous_headings":"","what":"Get antineoplastic drugs and drug regimens — get_onco_drugs","title":"Get antineoplastic drugs and drug regimens — get_onco_drugs","text":"Downloads preprocessed datasets local cache directory returns selected set drugs based various criteria set user. dataset comes list object, two elements: metadata - data frame metadata regarding drug resources used records - data frame drug records","code":""},{"path":"https://sigven.github.io/pharmaOncoX/reference/get_onco_drugs.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Get antineoplastic drugs and drug regimens — get_onco_drugs","text":"","code":"get_onco_drugs(   cache_dir = NA,   force_download = F,   exclude_salt_forms = T,   exclude_adc = T,   drug_is_targeted = F,   drug_is_approved = F,   drug_target = NULL,   drug_action_type = NULL,   drug_indication_main = NULL,   source_opentargets_only = F,   drug_has_blackbox_warning = F,   drug_approved_later_than = 1939,   drug_minimum_phase_any_indication = 0,   output_resolution = \"drug2target2indication\",   inhibitor_only = F,   is_alkylating_agent = F,   is_angiogenesis_inhibitor = F,   is_anthracycline = F,   is_antimetabolite = F,   is_ar_antagonist = F,   is_bet_inhibitor = F,   is_hedgehog_antagonist = F,   is_hdac_inhibitor = F,   is_hormone_therapy = F,   is_immune_checkpoint_inhibitor = F,   is_kinase_inhibitor = F,   is_monoclonal_antibody = F,   is_parp_inhibitor = F,   is_platinum_compound = F,   is_proteasome_inhibitor = F,   is_topoisomerase_inhibitor = F,   is_tubulin_inhibitor = F )"},{"path":"https://sigven.github.io/pharmaOncoX/reference/get_onco_drugs.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Get antineoplastic drugs and drug regimens — get_onco_drugs","text":"cache_dir local cache directory data retrieval force_download force download data remote repository even data exists cache exclude_salt_forms exclude salt forms drugs exclude_adc exclude antibody-drug conjugates (ADCs) drug_is_targeted logical indicating resulting drug records contain drugs known drug targets drug_is_approved logical indicating resulting drug records contain approved drugs drug_target character vector drug targets (gene symbols) drug records included results drug_action_type character vector drug action types include drug record list - possible values \"INHIBITOR\",\"AGONIST\",\"MODULATOR\",\"ANTAGONIST\",\"BLOCKER\",\"ACTIVATOR\",\"BINDING AGENT\",\"OPENER\", \"STABILISER\",\"CROSS-LINKING AGENT\",DISRUPTING AGENT\",\"\" drug_indication_main character vector main tumor types drug(s) indicated possible values \"Adrenal Gland\",\"Biliary Tract\",\"Bladder/Urinary Tract\",\"Bone\",\"Breast\",\"Cervix\",\"CNS/Brain\", \"Colon/Rectum\",\"Esophagus/Stomach\",\"Eye\",\"Head Neck\",\"Kidney\",\"Liver\",\"Lung\",\"Lymphoid\",\"Myeloid\",\"Ovary/Fallopian Tube\", \"Pancreas\",\"Penis\",\"Peripheral Nervous System\",\"Peritoneum\",\"Pleura\",\"Prostate\",\"Skin\",\"Soft Tissue\",\"Testis\",\"Thymus\", \"Thyroid\",\"Uterus\",\"Vulva/Vagina\" source_opentargets_only logical indicating resulting drug records contain drug records Open Targets Platform drug_has_blackbox_warning logical indicating resulting drug records contain drugs black box warnings drug_approved_later_than include records drugs approved later date (year) drug_minimum_phase_any_indication include drug records clinical phase (indication) greater equal phase output_resolution dictate output record resolution ('drug','drug2target','drug2target2indication') inhibitor_only logical indicating return drugs inhibitory mechanism--action is_alkylating_agent logical indicating drug class wanted is_angiogenesis_inhibitor logical indicating drug class wanted is_anthracycline logical indicating drug class wanted is_antimetabolite logical indicating drug class wanted is_ar_antagonist logical indicating drug class wanted is_bet_inhibitor logical indicating drug class wanted is_hedgehog_antagonist logical indicating drug class wanted is_hdac_inhibitor logical indicating drug class wanted is_hormone_therapy logical indicating drug class wanted is_immune_checkpoint_inhibitor logical indicating drug class wanted is_kinase_inhibitor logical indicating drug class wanted is_monoclonal_antibody logical indicating drug class wanted is_parp_inhibitor logical indicating drug class wanted is_platinum_compound logical indicating drug class wanted is_proteasome_inhibitor logical indicating drug class wanted is_topoisomerase_inhibitor logical indicating drug class wanted is_tubulin_inhibitor logical indicating drug class wanted","code":""},{"path":"https://sigven.github.io/pharmaOncoX/reference/get_onco_drugs.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Get antineoplastic drugs and drug regimens — get_onco_drugs","text":"records data frame contains following columns (selected columns shown based value output_resolution) drug_id - drug identifier (pharmaOncoX) drug_name - primary drug name (upper case, NCI Thesaurus) drug_type - type drug molecule (Antibody, small molecule etc) molecule_chembl_id - ChEMBL compound identifier drug_action_type - main action elicited drug (antagonist, inhibitor, stabiliser etc) drug_alias - collection unambiguous drug aliases (separated '|') nci_concept_definition - detailed description drug mechanism--action (NCI Thesaurus) opentargets - logical - drug found Open Targets Platform resource is_salt - logical - drug record represents salt form (excluded default) is_adc - logical - drug record represents antibody-drug conjugate (ADC - excluded default) drug_blacbox_warning - logical indicating drug blackbox warning nci_t - NCI thesaurus identifier comb_regimen_indication - logical whether use drug given condition context drug combination immune_checkpoint_inhibitor - logical indicating drug immune checkpoint inhibitor topoisomerase_inhibitor - logical indicating drug topoisomerase inhibitor tubulin_inhibitor - logical indicating drug tubulin inhibitor kinase_inhibitor - logical indicating drug kinase inhibitor hdac_inhibitor - logical indicating drug HDAC inhibitor parp_inhibitor - logical indicating drug PARP inhibitor bet_inhibitor - logical indicating drug BET inhibitor ar_antagonist - logical indicating drug androgen receptor antagonist monoclonal_antibody - logical indicating drug antibody antimetabolite - logical indicating drug antimetabolite angiogenesis_inhibitor - logical indicating drug angiogenesis inhibitor alkylating_agent - logical indicating drug alkylating agent platinum_compound - logical indicating drug platinum compound anthracycline - logical indicating drug anthracycline proteasome_inhibitor - logical indicating drug proteasome inhibitor hormone_therapy - logical indicating drug hormone therapy hedgehog_antagonist - logical indicating drug hedgehog pathway antagonist fda_epc_category - FDA Established Pharmacologic Class (EPC) text phrase target_symbol - gene symbol drug target target_entrezgene - Entrez gene identifier drug target target_genename - gene name/description drug target target_ensembl_gene_id - Ensembl gene identifier drug target target_type - type drug target (single protein, protein family etc.) drug_max_phase_indication - maximum clinical phase drug (given indication) drug_approved_indication - logical indicating drug approved indication drug_year_first_approval - year drug first approved drug_max_ct_phase - maximum clinical phase drug (indication) disease_efo_id - EFO (Experimental Factor Ontology) identifier drug indication disease_efo_label - EFO (Experimental Factor Ontology) label drug indication primary_site - primary tumor site/type (obtained https://github.com/sigven/oncoPhenoMap) drug_clinical_source - underlying source drug entry (DailyMed, clinicaltrials.gov, FDA etc.) drug_clinical_id - drug clinical identifier (clinicaltrials.gov, DailyMed, FDA etc.)","code":""},{"path":"https://sigven.github.io/pharmaOncoX/reference/tidyeval.html","id":null,"dir":"Reference","previous_headings":"","what":"Tidy eval helpers — tidyeval","title":"Tidy eval helpers — tidyeval","text":"https://cran.r-project.org/web/packages/dplyr/vignettes/programming.html","code":""},{"path":"https://sigven.github.io/pharmaOncoX/news/index.html","id":"version-097-september-21st-2022","dir":"Changelog","previous_headings":"","what":"Version 0.9.7 (September 21st 2022)","title":"Version 0.9.7 (September 21st 2022)","text":"Upgraded sigven/oncoPhenoMap v0.4.0 Upgraded sigven/geneOncoX Updated biomarkers (CIViC database)","code":""},{"path":"https://sigven.github.io/pharmaOncoX/news/index.html","id":"version-096-september-10th-2022","dir":"Changelog","previous_headings":"","what":"Version 0.9.6 (September 10th 2022)","title":"Version 0.9.6 (September 10th 2022)","text":"Added logical argument inhibitor_only get_onco_drugs retrieve drugs inhibitory role respect mechanism--action Fixed minor bug parsing approved indications drugs Open Targets Platform","code":""},{"path":"https://sigven.github.io/pharmaOncoX/news/index.html","id":"version-095-september-7th-2022","dir":"Changelog","previous_headings":"","what":"Version 0.9.5 (September 7th 2022)","title":"Version 0.9.5 (September 7th 2022)","text":"Updated NCI Thesaurus (22.08e) Improved classification alkylating agents Improved drug salts detection Excluded several radio(immuno)conjugate entries","code":""},{"path":"https://sigven.github.io/pharmaOncoX/news/index.html","id":"version-093-september-1st-2022","dir":"Changelog","previous_headings":"","what":"Version 0.9.3 (September 1st 2022)","title":"Version 0.9.3 (September 1st 2022)","text":"Removed drug aliases coincide english words","code":""},{"path":"https://sigven.github.io/pharmaOncoX/news/index.html","id":"version-091-august-30th-2022","dir":"Changelog","previous_headings":"","what":"Version 0.9.1 (August 30th 2022)","title":"Version 0.9.1 (August 30th 2022)","text":"Added helper function retrieve drug biomarkers","code":""},{"path":"https://sigven.github.io/pharmaOncoX/news/index.html","id":"version-090-august-25th-2022","dir":"Changelog","previous_headings":"","what":"Version 0.9.0 (August 25th 2022)","title":"Version 0.9.0 (August 25th 2022)","text":"Complete restructring get_onco_drugs, data now longer provided within package, must downloaded cache directory provided user, utilizing googledrive package Currently, get_onco_drugs function provided, considering adding extended support drug biomarkers moving forward Now using lgr logging","code":""},{"path":"https://sigven.github.io/pharmaOncoX/news/index.html","id":"version-084-july-27th-2022","dir":"Changelog","previous_headings":"","what":"Version 0.8.4 (July 27th 2022)","title":"Version 0.8.4 (July 27th 2022)","text":"Updated NCI Thesaurus (22.07d) Updated biomarkers (CIViC/Mitelman database)","code":""},{"path":"https://sigven.github.io/pharmaOncoX/news/index.html","id":"version-083-july-1st-2022","dir":"Changelog","previous_headings":"","what":"Version 0.8.3 (July 1st 2022)","title":"Version 0.8.3 (July 1st 2022)","text":"Updated NCI Thesaurus (22.06d) Updated Open Targets Platform (2022.06) Updated biomarkers (CIViC)","code":""},{"path":"https://sigven.github.io/pharmaOncoX/news/index.html","id":"version-082-june-19th-2022","dir":"Changelog","previous_headings":"","what":"Version 0.8.2 (June 19th 2022)","title":"Version 0.8.2 (June 19th 2022)","text":"Added drugs NCI thesaurus Drug indication updates: (EFO/- https://github.com/sigven/oncoPhenoMap) Updated biomarkers (CIViC)","code":""},{"path":"https://sigven.github.io/pharmaOncoX/news/index.html","id":"version-081-june-2nd-2022","dir":"Changelog","previous_headings":"","what":"Version 0.8.1 (June 2nd 2022)","title":"Version 0.8.1 (June 2nd 2022)","text":"Data updates: NCI Thesaurus (22.05e)","code":""}]
